StreetInsider.com News Articles

Revolution Medicines to Report Financial Results for Third Quarter 2026 After Market Close on November 4, 2026

Wed, 21 Oct 2026 16:05:00 -0400

REDWOOD CITY, Calif., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers, today announced that it will report financial results for the third quarter of 2026 on Wednesday, November 4, 2026, after market close. At 4:30 p.m. ET that day (1:30 p.m. PT), members of Revolution Medicines’ senior management team will host a webcast to discuss the financial results for the quarter and provide an update on corporate progress.

To listen to the live webcast,

Revolution Medicines to Report Financial Results for Third Quarter 2026 After Market Close on November 4, 2026

Wed, 21 Oct 2026 16:05:00 -0400

To listen to the live webcast,

Revolution Medicines starts Phase 3 trial of zoldonrasib for lung cancer

Tue, 20 Oct 2026 08:01:49 -0400

Revolution Medicines, Inc. (Nasdaq: RVMD) announced it has begun treating patients in RASolve 308, a global Phase 3 clinical trial evaluating zoldonrasib in combination with pembrolizumab and platinum-based chemotherapy as a first-line treatment for adults with metastatic RAS G12D non-squamous non-small cell lung cancer (NSCLC).

The randomized, double-blind trial (NCT07777822) compares zoldonrasib plus pembrolizumab and chemotherapy against placebo plus pembrolizumab and chemotherapy. The primary endpoint is progression-free survival, with key secondary endpoints including overall survival, objective response rate, duration of response, safety and tolerability, and patient-reported outcomes.

Zoldonrasib is an investigational oral RAS(ON) G12D-selective covalent inhibitor. RAS G12D mutations occur in approximately

Revolution Medicines Begins Treating Patients in Phase 3 RASolve 308 Trial Evaluating Zoldonrasib in Combination with Pembrolizumab and Chemotherapy as First-Line Treatment for Patients with Metastati

Tue, 20 Oct 2026 08:00:00 -0400

REDWOOD CITY, Calif., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers, today announced that it has begun treating patients in RASolve 308, a global Phase 3 clinical trial evaluating zoldonrasib, an investigational, RAS(ON) G12D-selective inhibitor, in combination with standard of care pembrolizumab plus chemotherapy as a first-line treatment in adult patients with metastatic RAS G12D non-squamous non-small cell lung cancer (NSCLC).

“Patients with metastatic RAS G12D non-squamous NSCLC, occurring in approximately 4% of cases,

Revolution Medicines Begins Treating Patients in Phase 3 RASolve 308 Trial Evaluating Zoldonrasib in Combination with Pembrolizumab and Chemotherapy as First-Line Treatment for Patients with Metastati

Tue, 20 Oct 2026 08:00:00 -0400

“Patients with metastatic RAS G12D non-squamous NSCLC, occurring in approximately 4% of cases,

Revolution (RVMD) PT Raised to $241 at Truist Securities; 'Longer-Term Thesis Holds Firm'

Mon, 19 Oct 2026 10:02:07 -0400

(Updated - October 19, 2026 10:02 AM EDT)

Truist Securities analyst Gregory Renza raised the price target on Revolution (NASDAQ: RVMD) to $241.00 (from $240.00) while maintaining a Buy rating.

The analyst commented: "Launch Bar Moves Higher; Longer-Term Thesis Holds Firm; Rasonque's rising launch expectations raise the bar for 3Q though we see the quarter as an early checkpoint in our broader RAS thesis. As one directional indicator, we raise our 3Q26 estimates to $19.5M from $14.3M, still below ~$26M consensus & elevated buy-side bar, with script capture, inventory, and EAP conversion leaving a wide range of outcomes. We view patient uptake

Revolution (RVMD) PT Raised to $241 at Truist Securities; 'Longer-Term Thesis Holds Firm'

Mon, 19 Oct 2026 10:02:07 -0400

(Updated - October 19, 2026 10:02 AM EDT)

Truist Securities analyst Gregory Renza raised the price target on Revolution (NASDAQ: RVMD) to $241.00 (from $240.00) while maintaining a Buy rating.

Guggenheim Reiterates Buy Rating on Revolution (RVMD)

Fri, 16 Oct 2026 07:54:17 -0400

Guggenheim analyst Michael Schmidt reiterated a Buy rating and $275.00 price target on Revolution (NASDAQ: RVMD).

The analyst commented: "RVMD announced that the EMA's CHMP has issued a positive opinion recommending EU approval of daraxonrasib ("Rasonque") as once-daily oral monotherapy, based on results from the Phase 3 RASolute 302 trial. RVMD started submitting the MAA application in early July, leveraging an expedited phased review process under the EMA’s Cancer Medicines Pathfinder project. We think it's likely that the early CHMP opinion results in Rasonque EMA already before YE26, ahead of our expectations, representing a possible upside scenario (we don't currently model

Jefferies Highlights Top Mid-Cap Biotech Stocks Ahead of Earnings

Fri, 16 Oct 2026 06:23:36 -0400

Investing.com -- Jefferies analysts identified their preferred mid-cap biotechnology stocks ahead of third-quarter earnings, with Oncorus (ONC) emerging as their top commercial pick, followed by Revolution Medicines (RVMD) and Alnylam Pharmaceuticals (ALNY). The firm made several price target adjustments across its coverage universe while maintaining buy ratings on select names.

The analysts noted they are closely monitoring earnings results for specific catalysts, including first revenue reports, potential earnings beats, and pipeline updates across their mid-cap biotech coverage.

1. Oncorus (ONC)

Jefferies rates the stock Buy with a $410 price target, up from $405. The firm models third-quarter Brukinsa revenue at approximately $1.36 billion

Jefferies Highlights Top Mid-Cap Biotech Stocks Ahead of Earnings

Fri, 16 Oct 2026 06:23:36 -0400

1. Oncorus (ONC)

Jefferies rates the stock Buy with a $410 price target, up from $405. The firm models third-quarter Brukinsa revenue at approximately $1.36 billion

Jefferies Highlights Top Mid-Cap Biotech Stocks Ahead of Earnings

Fri, 16 Oct 2026 06:23:36 -0400

1. Oncorus (ONC)

Jefferies rates the stock Buy with a $410 price target, up from $405. The firm models third-quarter Brukinsa revenue at approximately $1.36 billion

William Blair Starts Revolution (RVMD) at Outperform

Fri, 16 Oct 2026 02:51:05 -0400

William Blair analyst Alethia Young initiates coverage on Revolution (NASDAQ: RVMD) with a Outperform rating.

The analyst comments: “We are initiating coverage of Revolution Medicines with an Outperform rating and a DCF based valuation of $226 per share. RevMed has focused on drugging RAS since its founding in 2014, and that investment is now paying off. Rasonque (daraxonrasib) was approved in August 2026 for previously treated metastatic pancreatic cancer, and the company has seven ongoing or planned Phase III trials across pancreatic and lung cancer, one of the broadest RAS development plans in the space.

We believe RevMed will maintain its dominant

William Blair Starts Revolution (RVMD) at Outperform

Fri, 16 Oct 2026 02:51:05 -0400

William Blair analyst Alethia Young initiates coverage on Revolution (NASDAQ: RVMD) with a Outperform rating.

We believe RevMed will maintain its dominant

Revolution Medicines' daraxonrasib gets positive EU panel opinion

Thu, 15 Oct 2026 09:46:01 -0400

Revolution Medicines, Inc. (NASDAQ: RVMD) announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending marketing authorization for RASONQUE (daraxonrasib) in the European Union for the treatment of adult patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy.

The recommendation is based on results from the Phase 3 RASolute 302 trial, in which RASONQUE reduced the risk of death by 60% compared with chemotherapy in the overall study population, with a hazard ratio of 0.40 (95% CI: 0.30–0.53; p<0.0001). Median overall survival was 13.2 months with

Revolution Medicines’ RASONQUE(™) (daraxonrasib) Receives Positive CHMP Opinion Recommending Marketing Authorization in European Union for Metastatic Pancreatic Cancer

Thu, 15 Oct 2026 09:45:00 -0400

Recommendation based on results from Phase 3 RASolute 302 trial, which demonstrated a 60% reduction in risk of death compared with chemotherapy in the overall study population with statistically significant and clinically meaningful improvements across all primary and key secondary endpoints, regardless of tumor RAS mutation status
Positive CHMP opinion follows an expedited phased review of RASONQUE under the EMA’s Cancer Medicines Pathfinder project based on its potential to address a high unmet medical need

REDWOOD CITY, Calif., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a global, commercial-stage oncology company

Revolution Medicines’ RASONQUE(™) (daraxonrasib) Receives Positive CHMP Opinion Recommending Marketing Authorization in European Union for Metastatic Pancreatic Cancer

Thu, 15 Oct 2026 09:45:00 -0400

Recommendation based on results from Phase 3 RASolute 302 trial, which demonstrated a 60% reduction in risk of death compared with chemotherapy in the overall study population with statistically significant and clinically meaningful improvements across all primary and key secondary endpoints, regardless of tumor RAS mutation status
Positive CHMP opinion follows an expedited phased review of RASONQUE under the EMA’s Cancer Medicines Pathfinder project based on its potential to address a high unmet medical need

REDWOOD CITY, Calif., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a global, commercial-stage oncology company

Revolution (RVMD) PT Raised to $260 at RBC Capital

Wed, 14 Oct 2026 08:57:27 -0400

RBC Capital analyst Leonid Timashev raised the price target on Revolution (NASDAQ: RVMD) to $260.00 (from $259.00) while maintaining a Outperform rating.

Form 8-K Revolution Medicines, For: Oct 08

Tue, 13 Oct 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20261013/27181568.html

Revolution (RVMD) PT Raised to $259 at RBC Capital

Thu, 08 Oct 2026 08:27:35 -0400

RBC Capital analyst Leonid Timashev raised the price target on Revolution (NASDAQ: RVMD) to $259.00 (from $251.00) while maintaining a Outperform rating.

Revolution (RVMD) PT Raised to $240 at Truist Securities

Wed, 07 Oct 2026 07:14:30 -0400

Truist Securities analyst Gregory Renza raised the price target on Revolution (NASDAQ: RVMD) to $240.00 (from $239.00) while maintaining a Buy rating.

Revolution Medicines starts Phase 3 trial of drug combo for pancreatic cancer

Mon, 05 Oct 2026 08:01:08 -0400

Revolution Medicines, Inc. (Nasdaq: RVMD) announced it has begun enrolling patients in RASolute 309, a global, randomized, open-label Phase 3 clinical trial evaluating the combination of RASONQUE (daraxonrasib) and zoldonrasib as a first-line treatment for adults with metastatic RAS G12D pancreatic adenocarcinoma (PDAC).

The trial compares the drug combination against gemcitabine and nab-paclitaxel, a standard chemotherapy regimen. The dual primary endpoints are progression-free survival and overall survival. Key secondary endpoints include objective response rate, duration of response, safety and tolerability, pharmacokinetics, and patient-reported outcomes.

According to the company, RAS G12D is the most common RAS mutation in PDAC, occurring in approximately 40%

Revolution Medicines Begins Treating Patients in Phase 3 RASolute 309 Trial Evaluating RASONQUE™ (daraxonrasib) Plus Zoldonrasib as First-Line Treatment for Metastatic RAS G12D Pancreatic Cancer

Mon, 05 Oct 2026 08:00:00 -0400

REDWOOD CITY, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers, today announced that it has begun treating patients in RASolute 309, a global, randomized Phase 3 clinical trial evaluating the combination of RASONQUE (daraxonrasib), a RAS(ON) multi-selective inhibitor, and zoldonrasib, an investigational RAS(ON) G12D-selective inhibitor, as a first-line treatment in adult patients with metastatic RAS G12D pancreatic adenocarcinoma (PDAC).

“RAS G12D is the most common RAS variant in PDAC,” said Alan Sandler, M.D.,

Revolution Medicines Begins Treating Patients in Phase 3 RASolute 309 Trial Evaluating RASONQUE™ (daraxonrasib) Plus Zoldonrasib as First-Line Treatment for Metastatic RAS G12D Pancreatic Cancer

Mon, 05 Oct 2026 08:00:00 -0400

“RAS G12D is the most common RAS variant in PDAC,” said Alan Sandler, M.D.,

Leerink Resumes Revolution (RVMD) at Outperform

Mon, 05 Oct 2026 06:10:20 -0400

Leerink resumes coverage on Revolution (NASDAQ: RVMD) with a Outperform rating and a price target of $288.00.

For an analyst ratings summary and ratings history on Revolution click here. For more ratings news on Revolution click here.

Shares of Revolution closed at $206.64 yesterday.

Form 4 Revolution Medicines, For: Sep 29 Filed by: Sandler Alan B.

Thu, 01 Oct 2026 18:00:00 -0400

si-local-file:///var/storage/secattach/20261001/27137476.html